StockpollyBeta
Get App
Popularity #5,125
PLUR · NASDAQ · Biotechnology

Pluri (PLUR)

Expands cells for therapies, manufacturing and cultivated-food ventures.

$1.10
After hours−0.01 (−0.90%)
At close$1.11(+3.74%)

  1. Pluri (PLUR) to Post Earnings on Wednesday

    Defense World

  2. Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

    GlobeNewsWireFinancing

  3. Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

    GlobeNewsWireM&A

  4. Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

    GlobeNewsWire

  5. Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

    GlobeNewsWire

  6. Pluri Inc. (NASDAQ:PLUR) Sees Large Increase in Short Interest

    Defense World

  7. Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

    GlobeNewsWire

  8. Pluri (NASDAQ:PLUR) Stock Price Down 12.7% – Here’s Why

    Defense World

  9. Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

    GlobeNewsWire

  10. Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

    GlobeNewsWire

  11. Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

    GlobeNewsWire

  12. Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

    GlobeNewsWire

  13. Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

    GlobeNewsWire

  14. Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

    Accesswire

  15. BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

    PRNewsWire

  16. Plurilock Corporate Update for Shareholders

    Newsfile Corp

  17. Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

    GlobeNewsWire

  18. Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

    GlobeNewsWire

  19. U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

    GlobeNewsWire

  20. Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

    GlobeNewsWire